From the American Society of Clinical Oncology in cooperation with the Food and Drug Administration (FDA) and as a service to our members, ASCO will periodically distribute information about newly approved therapies for cancer patients. This helps FDA inform oncologists and professionals in oncology-related fields about recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The American Society of Clinical Oncology (ASCO) today released a position statement on state drug repository programs, outlining ASCO’s support for drug repository programs solely for oral medications provided they are maintained within a closed system. The Society also makes recommendations to help ensure that these programs are implemented appropriately, with sufficient patient protections in place.
This Cancer Prevention Month, the American Society of Clinical Oncology (ASCO) is supporting the American Institute of Cancer Research’s (AIRC) efforts to spread awareness about ways to help prevent a cancer diagnosis.
The 2020 general election is right around the corner, and all 435 members of the United States (U.S.) House of Representatives—and 35 U.S. Senators—are up for re-election. This means that Members of Congress will be spending more time in their home district or state this year and are more available for in-district meetings with constituents as a result. You could even invite your lawmakers to visit your practice.
On February 18, 106 organizations representing patients, providers, medical researchers, survivors, and families joined together to urge Congress to include the bipartisan CLINICAL TREATMENT Act (H.R. 913) in the upcoming ‘must pass’ healthcare extenders package, which is expected to pass this spring.
The meetings focused on drug pricing, access to clinical trials, Medicaid expansion and block grants, accelerated drug approval pathways, and other issues affecting people with cancer and their oncology care teams.
The Association for Clinical Oncology (ASCO) is calling on Members of Congress to continue their support for federally funded research by providing $44.7 billion for the National Institutes of Health (NIH), including $6.9 billion for the National Cancer Institute (NCI) in Fiscal Year (FY) 2021. The $3 billion funding increase for NIH will help the agency continue to regain some of the ground it lost after years of effectively flat budgets so the U.S. biomedical research enterprise can continue its important work in support of new advances and cures for patients.
Thirty-three practices in three countries have committed to providing high quality care by receiving the Quality Oncology Practice Initiative (QOPI®) Certification in the fourth quarter of 2019. The Association for Clinical Oncology (Association) applauds the work of these practices to ensure a better and healthier future.
“The American Society of Clinical Oncology (ASCO) applauds the Centers for Medicare & Medicaid Services (CMS) for reflecting recommendations in the Society’s position statement on pharmacy benefit managers (PBMs) in the agency’s 2021 and 2022 Medicare Advantage and Part D proposed rule.
The American Society of Clinical Oncology (ASCO) Research Community Forum (RCF) is holding a free, two-part webinar on Food and Drug Administration (FDA) audit readiness, which will take participants on a journey through the FDA inspection process.
On January 30, Jerome Seid, MD, FACP, testified during a hearing of the Michigan State Senate Committee on Health Policy and Human Services in support of SB 612, a bill that would make important reforms to prior authorization and step therapy protocols. Dr. Seid is a member of the Association for Clinical Oncology (ASCO) and past president of the Michigan Society of Hematology and Oncology (MSHO).
As a practicing hematologist and oncologist in Warren, Michigan, Dr. Seid provided first-hand experience to the Committee on how prior authorization impacts his patients.
The Centers for Medicare & Medicaid Services (CMS) announced that it is expanding its coverage of next generation sequencing (NGS) for use as a diagnostic tool for certain patients with cancer.
The American Society of Clinical Oncology's (ASCO) Quality Oncology Practice Initiative (QOPI®) Round 1 of reporting is open for data abstraction. Round 1 will close on June 5, 2020, and final reports will be available approximately four weeks after the round closes. To get started, go to the registration portal and log in.
The American Society of Clinical Oncology (ASCO) released a position statement, “Block Grants in Medicaid & Their Impact on Cancer Care,” summarizing the Society’s concerns about the potential negative impact that recent proposals to establish annual limits on federal funding for Medicaid—or block grants—could have on patients with cancer. The statement urges state and federal policymakers not to enact, apply for, or advance any proposals to establish block grants for Medicaid programs.